Significantly, our initial studies on two independent cohorts of 693 and 652 gliomas (accessible through the CGGA and TCGA projects, respectively) showed an increased gene expression of ADAMTS1 in more advanced glioma grades, and the overall survival data also supported the impact of this protease as a bad prognosis factor. The gene discussed is ADAMTS1; the disease is glioma.